Table 1.

Demographic features of CLAAS cohort versus all cocaine users.

CharacteristicsCLAAS, n = 50Cocaine+, n = 2740UnivariateMultivariate
OR (95% CI)p1OR (95% CI)p2
Age3, yrs, median (min, max)46 (21, 63)45 (18, 85)NA0.63734NANA
Sex, female28 (56)895 (32.7)2.62 (1.49–4.61)0.00053.15 (1.74–5.69)0.0001
Vital status, alive535 (70)2511 (91.64)0.21 (0.11–0.40)< 0.00010.20 (0.11–0.38)< 0.0001
Race, self-identified
  White30 (60)1335 (48.7)1.58 (0.89–2.79)0.11391.55 (0.86–2.79)0.149
  Black/African American10 (20)1083 (39.53)0.38 (0.19–0.77)0.00510.37 (0.18–0.77)0.007
  Nonwhite/nonblack10 (20)322 (11.75)1.82 (0.90–3.68)0.0901.92 (0.94–3.92)0.074
  Hispanic and Mexican/Mexican American4 (8)35 (1.28)6.72 (2.29–19.70)< 0.00018.46 (2.71–26.47)0.0002
  Native American/Alaska Native4 (8)134 (4.89)1.69 (0.60–4.77)0.3154.46 (1.51–13.17)0.007
  Asian1 (2)NANANANANA
  Other/Unknown1 (2)NANANANANA
  • Values are n (%) unless otherwise specified.

  • 1 Chi-square test, 2-sided (except where otherwise indicated).

  • 2 Logistic regression analysis, controlling for age, sex, vital status, and race.

  • 3 Age at first positive cocaine test result.

  • 4 Mann-Whitney U test, 2-sided.

  • 5 As of March 2018. CLAAS: cocaine/levamisole-associated autoimmunity syndrome; NA: not assessed.